

1 A randomized double-blind placebo-controlled trial of Guanfacine Extended Release for  
2 aggression and self-injurious behavior associated with Prader-Willi Syndrome

3

4

5 Deepan Singh<sup>1\*</sup>, Michael Silver<sup>2</sup>, Theresa Jacob<sup>1, 3</sup>

6

7

8 <sup>1</sup> Department of Psychiatry, Maimonides Medical Center, Brooklyn, New York

9 <sup>2</sup> Research Administration, Maimonides Medical Center, Brooklyn, New York

10 <sup>3</sup> Clinical and Translational Research Labs, Maimonides Medical Center, Brooklyn, New York

11

12

13 \* Corresponding Author

14 Email: [desingh@maimo.org](mailto:desingh@maimo.org) (DS)

15

16

17 Short title:

18 Guanfacine XR Against Behavioral Problems in PWS

19

## 20 **Abstract**

21 **Introduction:** Prader-Willi Syndrome (PWS), a rare genetic disorder, affects development and  
22 behavior, frequently resulting in self-injury, aggression, hyperphagia, oppositional behavior,  
23 impulsivity and over-activity causing significant morbidity. Currently, limited therapeutic options  
24 are available to manage these neuropsychiatric manifestations. The aim of this clinical trial was to  
25 assess the efficacy of guanfacine-extended release (GXR) in reducing aggression and self-injury  
26 in individuals with PWS.

27 **Trial Design:** Randomized, double-blind, placebo-controlled trial conducted under IRB approval.

28 **Methods:** Subjects with a diagnosis of PWS, 6-35 years of age, with moderate to severe aggressive  
29 and/or self-injurious behavior as determined by the Clinical Global Impression (CGI)-Severity  
30 scale, were included in an 8-week double-blind, placebo-controlled, fixed-flexible dose clinical  
31 trial of GXR, that was followed by an 8-week open-label extension phase. Validated behavioral  
32 instruments and physician assessments measured the efficacy of GXR treatment, its safety and  
33 tolerability.

34 **Results:** GXR was effective in reducing aggression/agitation and hyperactivity/noncompliance as  
35 measured by the Aberrant Behavior Checklist (ABC) scales ( $p=0.03$ ). Overall aberrant behavior  
36 scores significantly reduced in the GXR arm. Aggression as measured by the Modified Overt  
37 Aggression Scale (MOAS) also showed a significant reduction. Skin-picking lesions as measured  
38 by the Self Injury Trauma (SIT) scale decreased in response to GXR. No serious adverse events  
39 were experienced by any of the study participants. Fatigue /sedation was the only adverse event  
40 significantly associated with GXR. The GXR group demonstrated significant overall clinical  
41 improvement as measured by the CGI-Improvement (CGI-I) scale. ( $p<0.01$ ).

42 **Conclusion:** Findings of this pragmatic trial strongly support the use of GXR for treatment of  
43 aggression, skin picking, and hyperactivity in children, adolescents, and adults with PWS.

44

## 45 **Trial Registration**

46 ClinicalTrials.gov Identifier: [NCT05657860](https://clinicaltrials.gov/ct2/show/study/NCT05657860)

47

48

## 49 **Introduction**

50 Prader-Willi syndrome (PWS) is a rare, complex multisystem genetic disorder, which  
51 includes hypothalamic dysfunction, cognitive and behavioral problems, increased anxiety, and  
52 compulsive behaviors.<sup>1, 2</sup> It is the most common genetic cause of morbid obesity in children.<sup>2</sup>  
53 While hyperphagia is seen as the *sine qua non* of PWS, other behavioral symptoms such as  
54 aggression, oppositional behavior, and temper tantrums, are common and cause significant distress  
55 to patients and caregivers.<sup>3, 4, 5</sup> PWS also has a high prevalence of self-injurious behavior such  
56 as skin-picking, as well as repetitive motor activity, impulsivity, and hyperactivity.<sup>6, 7, 8, 9</sup> Despite  
57 the high prevalence of behavioral disturbances in PWS, evidence-based pharmacological treatment  
58 options for them remain limited.<sup>10</sup> In fact, at the time of this writing, there are no published results  
59 from any randomized controlled clinical trials evaluating the efficacy of any agent against the  
60 common behavioral disturbances seen in PWS except for hyperphagia. This is particularly  
61 concerning given that close to half of all children between ages 11-17 and over 65% of all adults

62 with PWS are on at least one prescribed psychotropic medication with most of them requiring  
63 more than one medication.<sup>11</sup>

64 Currently, serotonin reuptake inhibitors (SRIs) and atypical antipsychotics are the most  
65 frequently utilized medications to manage behavioral problems in PWS.<sup>11</sup> Both these classes of  
66 medications are associated with the potential for developing or worsening metabolic syndrome.<sup>12,</sup>  
67 <sup>13, 14, 15</sup> Due to the high risk of obesity in PWS, it is important to avoid weight gain-inducing  
68 agents as much as possible. Furthermore, there have been reports of the development of psychotic  
69 symptoms such as auditory/visual hallucinations and paranoid delusions with the use of SRIs and  
70 serotonin-agonists, making serotonergic agents potentially dangerous in this population.<sup>16, 17</sup>  
71 Impulsivity and hyperactivity are well-known presenting signs of attention-deficit/hyperactivity  
72 disorder (ADHD), and as many as 25% of the patients with PWS exhibit these symptoms.<sup>7</sup>  
73 Stimulants for the management of impulsivity and hyperactivity may sometimes worsen mood,  
74 and irritability, and chronic use of stimulants may lead to an increase in skin-picking behavior.<sup>18</sup>  
75 Although N-acetyl cysteine and oxytocin have been suggested for the management of skin-picking  
76 behaviors, safe and effective modalities remain sparse for the management of behavioral  
77 symptoms in PWS.<sup>19, 20, 21, 1</sup>

78 Guanfacine extended-release (GXR) is a postsynaptic  $\alpha_2$ -adrenoceptor agonist approved  
79 by the Food and Drug Administration (FDA) for the management of ADHD.<sup>22, 23</sup> Guanfacine is  
80 proposed to work by moderating the activity of the left dorsolateral prefrontal cortex associated  
81 with the emotional biasing of response execution, thus reducing impulsivity.<sup>24</sup> Medications that  
82 operate as  $\alpha_2$ -adrenoceptor agonists such as guanfacine are beneficial in treating disruptive and  
83 aggressive behaviors.<sup>25</sup> In addition, GXR has been demonstrated to be safe and effective for  
84 reducing hyperactivity, impulsivity, and distractibility in patients with autism.<sup>26, 27</sup> Most

85 importantly, GXR has had no reports of significant weight gain, worsening hyperphagia, or other  
86 metabolic side effects.<sup>28, 29</sup> A retrospective cohort study has demonstrated that GXR led to  
87 improvement in symptoms of skin picking, aggression/agitation, and ADHD in patients with PWS.  
88 <sup>30</sup> Given the significant morbidity caused by these behavioral problems in this already vulnerable  
89 population, novel evidence-based approaches are warranted for the management of aggression,  
90 impulsivity, and self-injury in PWS.<sup>31</sup> It was postulated that GXR is a safer treatment option for  
91 self-injurious and aggressive behaviors in PWS and we wanted to test this with a pragmatic  
92 approach.

93 The objective of this randomized, double-blind, placebo-controlled trial was to determine  
94 the efficacy of guanfacine extended release (GXR) in reducing aggression and self-injury in  
95 individuals with PWS, and to assess its safety and tolerability.

96

97

## 98 **Methods**

### 99 **Study Design**

100 This pragmatic two-phase 16-week study was designed to test the hypothesis that GXR is  
101 effective in reducing aggression and self-injury in individuals with PWS with moderate to severe  
102 aggressive and/or self-injurious behavior. In the first phase, the randomized controlled trial part,  
103 eligible subjects were randomly assigned in a 1:1 ratio, without stratification, to GXR or placebo  
104 for 8 weeks. This was the double-blind, placebo-controlled, fixed-flexible dose phase of the

105 clinical trial. Immediately following the blinded randomized trial period, an 8-week open-label  
106 extension was pursued to further define the efficacy and tolerability of GXR, as well as to establish  
107 its safety with a specific focus on metabolic profile.

108 The study was performed in accordance with all current applicable regulations, the  
109 International Conference on Harmonization of Good Clinical Practice, the principles of the  
110 Declaration of Helsinki and local ethical and legal requirements. It was approved by the  
111 Institutional Review Board (# 2020-11-03-MMC) and registered at ClinicalTrials.gov (identifier:  
112 NCT05657860). It was conducted in a mental health clinic setting of a large, urban, community-  
113 based teaching hospital in a major metropolis of the United States. The study recruitment period  
114 began March 1, 2021 and ended October 31, 2023. Study participants received complete  
115 information regarding the protocol during the consent process before enrollment. Written, IRB-  
116 approved informed consent was obtained from each participant's parent or legal guardian, and  
117 assent was obtained from each participant, as applicable.

## 118 **Inclusion/Exclusion Criteria**

119 To be eligible for inclusion, subjects had to be between 6 and 35 years of age with a  
120 diagnosis of PWS confirmed by genetic testing. In addition, a rating of moderate or above on the  
121 Clinical Global Impression - Severity scale (CGI-S) was required for inclusion. Females of  
122 childbearing potential had to have a negative urine pregnancy test at screening and baseline and to  
123 comply with any protocol contraceptive requirements. In addition, participants and their  
124 parent/legal guardian had to be willing, able, and likely to fully comply with the study procedures  
125 and restrictions defined in the protocol. Exclusionary criteria included a positive pregnancy test,  
126 swallowing difficulty, or the presence of clinically significant bradycardia or hypotension. Those

127 currently on GXR, actively enrolled in other studies, or with a lactose intolerance or allergy were  
128 also excluded. Subjects receiving antipsychotic medications due to a documented history of  
129 psychosis or bipolar disorder were allowed to continue taking the medication without dosage  
130 modification. The pragmatic approach of this trial also allowed growth hormone, thyroid hormone  
131 replacement treatment, and non-psychiatric medicines, to continue albeit without dosage  
132 modifications. Similarly, N-Acetyl Cysteine (NAC) and anticonvulsant medications if prescribed  
133 for seizures were allowed, with specific instructions to refrain from making any dosage changes  
134 during the trial period.

## 135 **Study Drug Administration**

136 The starting dose for all subjects was 1 mg per day. Subjects weighing less than 25 kg  
137 remained on the 1 mg dose until day 14. If the medication was well tolerated, the dose was raised  
138 to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. Subjects weighing  
139 25 kg or more were eligible for an increase to 2 mg at day 7, 3 mg at day 14, and 4 mg at day 21  
140 or day 28. The dose schedule was not fixed; the treating clinician could delay a planned increase  
141 or lower the dose to manage adverse effects. Medication was dispensed at the baseline visit and at  
142 the unblinding visit for the subsequent dosing period. GXR was administered as 1 mg capsules;  
143 placebo group received matching placebo capsules.

## 144 **Randomization and Blinding**

145 Subjects were randomly assigned to either the placebo or experimental (GXR) group in a  
146 1:1 ratio via a computer-generated randomization scheme with randomly permuted blocks of  
147 varying sizes, done by Pharmacy. As the first phase of this study was double-blinded, the study

148 pharmacist was the only team member aware of patient treatment assignments. Randomization  
149 occurred at baseline (visit 1). Unblinding was at week 8, and subjects continued treatment for 8  
150 more weeks (open-label phase).

## 151 **Assessments**

152 Baseline and follow-up assessments included the Aberrant Behavior Checklist, (ABC),  
153 Self-Injury Trauma (SIT) scale, physician-administered Clinical Global Impression – Severity  
154 (CGI-S; only at baseline), and CGI-Improvement (CGI-I) scales, Hyperphagia Questionnaire for  
155 use in PWS clinical trials (HQ-CT), Modified Overt Aggression Scale (MOAS), and the Epworth  
156 Sleepiness Scale (ESS) at biweekly study visits. The ABC includes an overall score and sub-scores  
157 to monitor irritability, lethargy, inappropriate speech, hyperactivity and stereotypies.

158 In addition, laboratory tests, medical and psychiatric histories, physical examination,  
159 electrocardiography (ECG), and vital signs evaluation were conducted at study visits. Daily  
160 monitoring of vitals and problematic behavior was performed by caregivers.

## 161 **Safety Monitoring**

162 Blood pressure and pulse rate were measured at each visit. Laboratory tests were conducted  
163 at baseline and were repeated at week 8 and week 16. An ECG was obtained at baseline and at  
164 week 8 to assess the impact of GXR on cardiac conduction. Adverse events were systematically  
165 reviewed and documented. Side effects were measured using open-ended clinician inquiry with  
166 questions about drowsiness, fatigue, decreased appetite, emotional/tearful, dry mouth, irritability,  
167 anxiety, headache, increased energy, mid-sleep waking, stomachache, constipation, increased



168 repetitive behavior, aggression, depressed mood, cough/congestion, self-injury, nausea, trouble  
169 falling asleep, dizziness, silly, weakness, diarrhea, vomiting, increased appetite, excessive talking,  
170 blurred vision, skin rash/eczema, nightmares, enuresis, motor tics, skin-picking, and pyrexia.

171 Subjects who were randomly assigned to placebo group and did not show a positive  
172 response by 8 weeks, were offered open-label treatment with GXR for 8 weeks. All subjects in  
173 this continuation phase were seen every 2 weeks for monitoring. Those unblinded and started on  
174 GXR were monitored weekly for the first 4 weeks of the continuation phase.

## 175 **Data Analysis**

176 Data were analyzed using an intent-to-treat approach. Patient baseline data were  
177 summarized via descriptive statistics such that continuous variables were summarized by means  
178 (SD) or medians (IQR) and categorical data by counts (%). Baseline factors (CGI-S, age, gender)  
179 as well as all study observations were presented within each group. In the analysis, distributions  
180 were compared between treatment groups at baseline via the Wilcoxon rank sum test. Finally, we  
181 created a repeated measures linear regression model for each outcome scale, using Generalized  
182 Estimating Equations (GEE) to account for within-subject variability, with the predictor of  
183 treatment, to assess the impact of treatment across the entire timeline of the study. An unstructured  
184 correlation matrix was assumed. All models were then plotted in a Forest Plot for ease of  
185 comparison. Two-sided p-values  $< 0.05$  were considered statistically significant. All analyses were  
186 conducted using SAS/STAT version 9.4 (SAS Institute Inc., Cary N.C. USA).

187

188

## 189 **Results**

### 190 **Demographics**

191 Over the study period, 65 patients with a clinical diagnosis of PWS were screened. Of  
192 these, 14 underwent randomization. Participant disposition in the study is shown in the CONSORT  
193 flow diagram (Fig 1). The study population included 11 males and 3 females, aged between 6 to  
194 35 years, carrying genetically confirmed diagnoses of PWS. Of these subjects, 78.5% were  
195 Caucasian, and 7% were Asian. Table 1 reviews the demographics of the participants. Subtype  
196 distribution showed that 29% of the subjects carried paternal deletion and 43% had maternal  
197 uniparental disomy. Further, the submitted test reports did not distinguish subtype in 28% of the  
198 participants.

199

200 **Fig 1. CONSORT flow diagram.** Participant disposition in double-blind, randomized placebo-  
201 controlled trial for GXR (guanfacine-extended release)

202

203

204 **Table 1. Baseline Demographics and Clinical Characteristics of Study Participants.**

		<b>Placebo (n=7)</b>	<b>Guanfacine XR (n=7)</b>	<b>P-value</b>
<b>Age (years)</b>		8 (8-16)	10 (7 - 10)	0.383
<b>Sex</b>	<i>Female</i>	1 (14.3%)	2 (28.6%)	1.000
	<i>Male</i>	6 (85.7%)	5 (71.4%)	
<b>Ethnicity</b>	<i>Hispanic or Latino</i>	1 (14.3%)	2 (28.6%)	1.000
	<i>Not Hispanic or Latino</i>	6 (85.7%)	5 (71.4%)	
<b>Race</b>	<i>Missing</i>	1 (14.3%)	0 (0%)	1.000
	<i>Asian</i>	0 (0%)	1 (14.3%)	
	<i>Middle Eastern</i>	0 (0%)	1 (14.3%)	
	<i>White</i>	6 (85.7%)	5 (71.4%)	
<b>Blood Pressure (mmHg)</b>	<i>Systolic</i>	123 (103 - 126)	103 (101 - 121)	0.383
	<i>Diastolic</i>	77 (68 - 81)	72 (60 - 74)	0.535
<b>Heart Rate (bpm)</b>		82 (63 - 101)	87 (74 - 101)	0.5
<b>ECG (QTcF)</b>		397 (384 - 413)	398 (391 - 413)	0.805
<b>Height (cm)</b>		147.32 (132.5 - 152)	136 (124.8 - 152.4)	0.456
<b>Weight (kg)</b>		65.8 (33.2 - 77.6)	48.2 (29.8 - 66.8)	0.318
<b>BMI (Body Mass Index)</b>		28.5 (18.7 - 35.2)	23.6 (18.1 - 30.7)	0.456

205 All numeric variables were summarized with median and IQR and compared across groups with a  
 206 *Wilcoxon Rank Sum Test*. All categorical variables were summarized with frequency and percentage and  
 207 compared across groups with a *Fisher Exact Test*.

208

## 209 **Patient Baseline Characteristics**

210 As seen in Table 2, there were no differences among the groups at baseline for any  
 211 measures, including severity of illness as measured by the CGI-S.

212

213

214 **Table 2. Subject Behavioral Measure Scores at Index Visit.**

Outcome Measures	Placebo (n=7)	GXR (n=7)	P-value
ABC	58 (45 - 67)	48 (24 - 70)	0.620
ABC - Subscale I, <i>Irritability</i>	21 (15 - 23)	15 (6 - 26)	0.710
ABC - Subscale II, <i>Social Withdrawal</i>	16 (5 - 20)	11 (2 - 24)	0.456
ABC - Subscale III, <i>Stereotypic Behavior</i>	2 (0 - 6)	0 (0 - 2)	0.383
ABC - Subscale IV, <i>Hyperactivity/Noncompliance</i>	16 (12 - 24)	9 (6 - 22)	0.209
ABC - Subscale V, <i>Inappropriate Speech</i>	5 (4 - 8)	7 (4 - 9)	0.710
CGI-S	6 (5 - 6)	5 (5 - 6)	0.535
ESS	10 (6 - 13)	7 (1 - 8)	0.383
HQ-CT	14 (8 - 16)	14 (6 - 25)	0.805
MOAS (total weighted score)	11 (11 - 17)	13 (9 - 17)	1.000
MOAS - <i>Verbal Aggression Subscale</i>	2 (1 - 2)	2 (2 - 2)	0.805
MOAS - <i>Aggression Against Property Subscale</i>	2 (2 - 4)	2 (0 - 4)	0.620
MOAS - <i>Autoaggression Subscale</i>	3 (3 - 3)	3 (3 - 6)	0.259
MOAS - <i>Physical Aggression Subscale</i>	4 (3 - 8)	8 (0 - 8)	0.902
SIT - <i>Number Index Score</i>	1 (1 - 2)	2 (1 - 2)	0.620
SIT - <i>Severity Index Score</i>	2 (1 - 5)	2 (1 - 3)	1.000

215 **ABC**, Aberrant Behavior Checklist; **CGI-S**, Clinical Global Impression – Severity scale; **ESS**, Epworth  
 216 Sleepiness; **HQ-CT**, Hyperphagia Questionnaire for use in PWS clinical trials; **MOAS**, Modified Overt  
 217 Aggression Scale; **SIT**, Self-Injury Trauma scale.

218 All numeric variables were summarized with median and IQR and compared across groups with a  
 219 *Wilcoxon Rank Sum Test*.

220

## 221 **Response to GXR**

222 In repeated measures linear regression models, using GEE and an unstructured correlation  
 223 matrix, there was a decrease in the Aberrant Behavior Checklist score of 9.962 points (95% CI: 19  
 224 - 0.8),  $p=0.03$ , in subjects receiving GXR treatment as seen in Table 3. A decrease in ABC subscale  
 225 IV (Hyperactivity) of 5.27 points (95% CI: 1.23 – 9.30),  $p=0.01$ , was also observed in this group.  
 226 While on GXR, subjects demonstrated a reduction in aggressive behaviors as reflected in the  
 227 decrease in MOAS score of 3.65 points (95% CI: 0.50 – 6.79),  $p=0.02$ . The number of skin-picking  
 228 lesions also decreased in response to GXR, as indicated by the SIT scale scores in the treatment

229 arm; however, this decrease was not significant in comparison to that observed in the placebo arm.  
 230 There was a highly significant improvement in the overall behavioral symptoms of participants on  
 231 GXR, as reflected by the lower scores in the psychiatrist-rated CGI-I scales [1.25 points, (95% CI:  
 232 0.47 – 2.04), p=0.002]. There were no other statistical differences observed in outcome measures.  
 233 Fig 2 demonstrates a schematic forest plot of the different effect sizes across measures.

234

235 **Table 3. GEE Models for Additional Outcomes and Scales.**

Outcome Measures	$\beta$	95% CI		P-value
		LCL	UCL	
ABC	-9.962	-19.136	-0.788	<b>0.033</b>
ABC - Subscale I, <i>Irritability</i>	-1.253	-5.08	2.574	0.521
ABC - Subscale II, <i>Social Withdrawal</i>	0.252	-1.918	2.421	0.821
ABC - Subscale III, <i>Stereotypic Behavior</i>	-0.447	-1.171	0.277	0.226
ABC - Subscale IV, <i>Hyperactivity/Noncompliance</i>	-5.266	-9.298	-1.233	<b>0.01</b>
ABC - Subscale V, <i>Inappropriate Speech</i>	-0.637	-1.398	0.123	0.10
CGI-S	-0.304	-0.938	0.329	0.347
CGI-I	-1.25	-2.036	-0.465	<b>0.002</b>
ESS	0.425	-2.684	3.533	0.789
HQ-CT	-4.94	-15.45	5.57	0.357
MOAS (total weighted score)	-3.645	-6.794	-0.496	<b>0.023</b>
SIT - <i>Number Index Score</i>	-0.639	-1.374	0.096	0.089
SIT - <i>Severity Index Score</i>	-1.121	-3.611	1.368	0.377

236 *ABC*, Aberrant Behavior Checklist; *CGI-S*, Clinical Global Impression – Severity scale; *CGI-I*; Clinical  
 237 Global Impression - Improvement scale; *ESS*, Epworth Sleepiness; *HQ-CT*, Hyperphagia Questionnaire  
 238 for use in PWS clinical trials; *MOAS*, Modified Overt Aggression Scale; *SIT*, Self-Injury Trauma scale.

239

240 **Fig 2. Forest plot.** A schematic of the different effect sizes across measures in the two study  
 241 groups based on GEE Models (Generalized Estimating Equations)

242

## 243 **Side Effects and Tolerability**

244           There were no serious adverse events (SAEs) reported by subjects in either of the study  
245 groups. However, subjects on GXR were more likely to experience fatigue 29% vs 93%,  $p = 0.012$ .  
246 Table 4 shows all the treatment-emergent adverse events observed among trial subjects in GXR  
247 and placebo groups. There were no other differences in the rate of adverse events amongst the  
248 groups.

249           There were no GXR-related clinically meaningful changes in ECG and QTc-related  
250 parameters. No significant changes in vital signs, or lab values were observed between the groups.  
251 The average stable dose of GXR at time of completion of the study was 2.75 mg daily.

252

253

254 **Table 4. Incidence of Adverse Events**

Adverse Event	Placebo (n=7)	GXR (n=14)	P-value
Anxiety	1 (14%)	2 (14%)	1.000
Depressed	1 (14%)	5 (36%)	0.615
Dry Mouth	1 (14%)	1 (7%)	0.490
Increased Appetite	2 (29%)	3 (21%)	0.583
Irritable Aggression	1 (14%)	5 (36%)	0.615
Constipation	0 (0%)	1 (7%)	1.000
Fatigue	2 (29%)	13 (93%)	<b>0.012</b>
Enuresis	1 (14%)	3 (21%)	1.000
Excessive Talking	0 (0%)	2 (14%)	1.000
Skin Picking	0 (0%)	2 (14%)	1.000
Diarrhea	2 (29%)	1 (7%)	0.172
Mild Sleep Awakening	0 (0%)	3 (21%)	0.522
Dizziness	0 (0%)	1 (7%)	1.000
Decreased Appetite	0 (0%)	1 (7%)	1.000
Difficult Swallowing	0 (0%)	1 (7%)	1.000
Headache	1 (14%)	1 (7%)	0.490
Increased Energy	0 (0%)	1 (7%)	1.000

255 Adverse events are expressed as frequencies (and percentage) of participants for each treatment-emergent  
256 adverse event and compared across groups with a *Fisher Exact Test*.

257

258

## 259 **Discussion**

260 Behavioral and psychiatric symptoms are common in the PWS patient population.  
261 Individuals with PWS may exhibit impulsive behavior, which can impede daily functioning and  
262 lead to risky behavior. <sup>6, 7, 32</sup> Furthermore, patients can exhibit aggression and temper tantrums,  
263 which leads to significant caregiver burden. <sup>5, 33</sup> Skin-picking is another behavioral symptom  
264 commonly seen in this patient population, which may get complicated with infections and scarring

265 at the site of damage.<sup>19</sup> The overall burden of illness over the lifetime of an individual with PWS  
266 is compounded by these behavioral problems.

267 Currently, the commonly used pharmacological treatment options for behavioral  
268 management in individuals with PWS are SRIs, stimulants, and atypical antipsychotics. Their use  
269 in PWS is widespread despite the lack of empirical placebo-controlled studies to demonstrate  
270 efficacy. These medications are associated with significant risks including weight gain for  
271 antipsychotics, psychosis for SRIs, and increased skin excoriation with stimulants. With the  
272 exception of NAC, options are limited for the treatment of skin-picking behavior.<sup>19, 20, 21, 1, 34</sup>  
273 Therefore, investigating relatively safe medication options that can effectively manage several  
274 impairing behavioral symptoms seen in PWS is warranted to positively impact the lives of patients  
275 and to reduce caregiver fatigue.

276 This randomized double-blind, placebo-controlled, fixed-flexible dose clinical trial with  
277 open-label continuation, was designed to explore the efficacy, safety, and tolerability of guanfacine  
278 extended release in the management of aggression and self-injurious behavior (skin picking) in  
279 individuals with PWS. The results of this study demonstrate that GXR ameliorates overall  
280 behavioral disturbances as measured by the ABC scale. GXR was particularly effective against  
281 hyperactivity in PWS. This finding is expected since GXR has established evidence for the  
282 treatment of ADHD in the general population.<sup>35, 36</sup> Additionally, GXR led to a significant  
283 reduction in aggressive behavior as measured by the MOAS. Our study also showed a positive  
284 response to GXR in terms of skin picking, with a reduction in the number of lesions in the treatment  
285 group, although it was not statistically significant as compared to that in the placebo group.



286 Notably, subjects on GXR showed a significant improvement in their overall presentation as  
287 measured by the CGI-I scale.

288 GXR was generally well tolerated with the most commonly reported side effect being  
289 fatigue, commensurate with the findings in the general population.<sup>37</sup> It is important to note that  
290 despite this, the overall level of daytime sleepiness as measured by the ESS did not show any  
291 statistical difference from placebo. This finding is of particular salience given the high rates of  
292 daytime sleepiness experienced in this population.<sup>38</sup> There were no serious adverse events  
293 reported in the GXR group. Another key factor to consider in this study is that, none of the subjects  
294 exposed to GXR experienced weight gain. There was no difference noted between the GXR and  
295 placebo groups with respect to ECG changes, blood pressure, or heart rate.

296 Several outcomes trended towards a positive response but failed to reach a statistical  
297 significance level. In particular, a positive signal was observed for hyperphagia and skin picking.  
298 These need to be confirmed in future studies with a larger sample size.

299 Individuals with PWS suffer from growth hormone (GH) deficiency, which contributes to  
300 the short stature and the central obesity. GH replacement therapy has shown beneficial effects in  
301 aiding linear growth, and restoring normal body composition, bone density, as well as lipid profile  
302 values in individuals with PWS.<sup>39 40</sup> At the time of this writing, GH is the only medication that  
303 has an FDA approved indication for the management of PWS.<sup>41</sup> Clonidine is an  $\alpha$ 2-adrenoceptor  
304 agonist similar to GXR, and both medications have been shown to increase GH levels in a dose-  
305 dependent manner. However, GXR is less sedating compared to clonidine and may be a better  
306 alternative in this setting.<sup>42</sup> Although not measured in the current study, the possible physical  
307 benefits of increased GH could indicate an additional advantage of GXR in comparison to other

308 medications used for the behavioral management of individuals with PWS. This could be further  
309 elucidated in prospective trials.

310

## 311 **Limitations**

312 The multiple limitations of this study need to be highlighted. Although there were no gender  
313 differences between the active and placebo arms, the majority of patients enrolled were male. A  
314 larger study could reduce the possibility of there being a gender based moderating effect on the  
315 results. A larger sample size would also allow stratification of the results by PWS genotype.  
316 Similarly, the participants were predominantly Caucasian hence limiting generalizability of  
317 findings. The study was conducted at a single site, limiting the diversity in participants that can be  
318 achieved from a multicenter study. It is challenging to establish external validity in a single-site  
319 study, due to limitations of accounting for the variance in environmental and practitioner-based  
320 factors. Another factor that must be considered is the relatively high prevalence of ADHD and  
321 autism in PWS.<sup>6</sup> Therefore, there is a possibility that the observed effects may be moderated by  
322 these co-existing conditions.

323 Despite these challenges to the study, the results of this clinical trial, along with prior  
324 knowledge of the side effects posed by the alternatives available to practitioners, suggests that  
325 GXR should be the first line treatment for behavioral problems, specifically aggression, irritability,  
326 and hyperactivity in individuals with PWS.

327

328

## 329 **Conclusions**

330 This randomized, fixed-flexible dose placebo-controlled clinical trial, with open label  
331 extension, aimed to provide a supporting framework for the utilization of GXR in the management  
332 of behavioral symptoms comorbid with PWS. The assessed symptoms included aggression,  
333 irritability, inattention/hyperactivity, and skin-picking. GXR treatment leads to global  
334 improvement in symptoms, particularly those related to behavioral disturbance in persons with  
335 PWS. Specifically, GXR reduces aggression and hyperactivity in this population. Additionally,  
336 there are possible beneficial effects on skin picking behavior. The most commonly reported side  
337 effect was fatigue, but overall daytime sleepiness was not worse than placebo. There were no  
338 serious adverse effects reported. GXR did not lead to any change in weight, heart rate, blood  
339 pressure, or cardiac rhythm, as compared to placebo. The results of this clinical trial suggests that  
340 GXR is an effective and relatively safe treatment modality for behavioral problems in patients with  
341 PWS.

## 342 **Clinical Significance**

343 Individuals with PWS often present with challenging behavioral disturbances such as  
344 aggression/agitation, skin-picking, and ADHD symptoms like impulsivity and inattention. Current  
345 management strategies for behavioral disturbances in PWS patients show limited efficacy and can  
346 have significant side effects. Although other studies have been conducted to assess treatment  
347 options against hyperphagia, this is the first randomized placebo-controlled trial examining the  
348 efficacy of a psychotropic medication against the behavioral manifestations of PWS. This

349 randomized placebo-controlled clinical trial demonstrated that GXR is effective in the  
350 management of behavioral disturbances in PWS while being well tolerated. The authors  
351 recommend that GXR be considered as a first line treatment strategy for the management of  
352 behavioral problems, especially aggression and hyperactivity, associated with PWS.

353

354

## 355 **Supporting Information**

356 **S1 Checklist. CONSORT Checklist**

357

358

## 359 **Acknowledgments**

360 The authors would like to thank our hospital pharmacists Jason Brady and Rina Evans for their  
361 invaluable contribution. We would also like to thank our clinical research coordinators Otuwe  
362 Anya and Hasan Mustafic, without whom this study would not have been possible.

363

364

## 365 **References**

---

<sup>1</sup> Miller JL, Tamura R, Butler MG, Kimonis V, Sulsona C, Gold JA et al. Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study. *Am J Med Genet A*. 2017;173A:1243-50.

<sup>2</sup> Butler MG. Prader-Willi Syndrome: Obesity due to Genomic Imprinting. *Curr Genomics*. 2011;12:204-15.

<sup>3</sup> Ogura K, Shinohara M, Kousaku O, Mori E. Frontal behavioral syndromes in Prader-Willi syndrome. *Brain Dev*. 2008;30:469-76.

<sup>4</sup> Arron K, Oliver C, Moss J, Berg K, Burbidge C. The prevalence and phenomenology of self-injurious and aggressive behaviour in genetic syndromes. *J Intellect Disabil Res*. 2011;55:109-20.

<sup>5</sup> Tunnicliffe P, Woodcock K, Bull L, Oliver C, Penhallow J. Temper outbursts in Prader-Willi syndrome: causes, behavioral and emotional sequence and responses by carers. *J Intellect Disabil Res*. 2014;58:134-50.

<sup>6</sup> Ogata H, Ihara H, Murakami N, Gito M, Kido Y, Nagai T. Autism spectrum disorders and hyperactive/impulsive behaviors in Japanese patients with Prader-Willi syndrome: a comparison between maternal uniparental disomy and deletion cases. *Am J Med Genet A*. 2014;164A:2180-6.

<sup>7</sup> Wigren M, Hansen S. ADHD symptoms and insistence on sameness in Prader-Willi syndrome. *J Intellect Disabil Res*. 2005;49:449-56.

---

<sup>8</sup> Greaves N, Prince E, Evans DW, Charman T. Repetitive and ritualistic behavior in children with Prader-Willi syndrome and children with autism. *J Intellect Disabil Res.* 2006;50:92-100.

<sup>9</sup> Banga A, Connor DF. Effectiveness of naltrexone for treating pathologic skin picking behavior in an adolescent with Prader-Willi syndrome. *J Child Adolesc Psychopharmacol.* 2012;22:396–8.

<sup>10</sup> Bonnot O, Cohen D, Thuilleaux D, Consoli A, Cabal S, Tauber M. Psychotropic treatments in Prader Willi syndrome: a critical review of published literature. *Eur J Pediatr.* 2016;175:9-18.

<sup>11</sup> Matesevac L, PATH for PWS Study 2021 Update: A Non-Interventional, Observational, Natural History Study of Serious Medical Events in Prader-Willi Syndrome. Presented in the PWSA-USA Medical & Scientific Conference 2021, Virtual. <https://www.pwsausa.org/2021-national-convention-session-recordings/>

<sup>12</sup> Kohn Y, Weizman A, Apter A. Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine. *Int J Eat Disord.* 2001;30:113-7.

<sup>13</sup> Kraemer S, Minarzyk A, Forst T, Kopf D, Hundemer HP. Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics—results from a German observational study. *BMC Psychiatry.* 2011;11:173.

<sup>14</sup> Hellings JA. Self-injurious behavior and serotonin in Prader-Willi syndrome. *Psychopharmacol Bull.* 1994;20:245-50.

---

<sup>15</sup> Warnock JK, Kestenbaum T. Pharmacologic treatment of severe skin-picking behaviors in Prader-Willi syndrome. Two case reports. *Arch Dermatol.* 1992;128:1623-5.

<sup>16</sup> Herguner S, Mukaddes NM. Psychosis associated with fluoxetine in Prader-Willi syndrome. *J Am Acad Child Adolesc Psychiatry.* 2007;46:944-45.

<sup>17</sup> Dennison EA, Raidoo BM, Cruz R, Raidoo D. A case of high-dose venlafaxine-related psychosis. *J Clin Psychopharmacol.* 2013;33:134–6.

<sup>18</sup> Kara T, Akaltun I. Newly Developed Skin Picking After Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder: Possible Mechanisms. *Clin Neuropharmacol.* 2018;41:28-30.

<sup>19</sup> Miller JL, Angulo M. An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. *Am J Med Genet A.* 2014;164A:421-4.

<sup>20</sup> Tauber M, Mantoulan C, Copet P, Jauregui J, Demeer G, Diene G, et al. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. *Orphanet J Rare Dis.* 2011;6:47.

<sup>21</sup> Kuppens RJ, Donze SH, Hokken-Koelega AC. Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial. *Clin Endocrinol (Oxf).* 2016;85:979-87.

---

<sup>22</sup> Website: “Drugs@FDA: FDA Approved Drug Products.” *Accessdata.fda.gov*, [www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=20088](http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=20088)

1. (Access date: July 09, 2018)

<sup>23</sup> Cruz MP. Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder. *P T*. 2010;35:448-51.

<sup>24</sup> Schulz KP, Clerkin SM, Fan J, Halperin JM, Newcorn JH. Guanfacine modulates the influence of emotional cues on prefrontal cortex activation for cognitive control. *Psychopharmacology (Berl)*. 2013;226:261-71.

<sup>25</sup> Pringsheim T, Hirsch L, Gardner D, Gorman DA. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. *Can J Psychiatry*. 2015;60:42-51.

<sup>26</sup> Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L et al. Research Units on Pediatric Psychopharmacology Autism Network. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. *Am J Psychiatry*. 2015;172:1197-206.

<sup>27</sup> Davis NO, Kollins SH. Treatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder. *Neurotherapeutics*. 2012;9:518-30.



---

<sup>28</sup> Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. *Eur Neuropsychopharmacol.* 2014;24:1861-72.

<sup>29</sup> Singh D, Kadakia N, Pinkhasov A. Significant reduction of aggression with guanfacine extended release in an adolescent with Prader-Willi syndrome. *J Child Adolesc Psychopharmacol.* 2015;25:376-7.

<sup>30</sup> Singh D, Wakimoto Y, Filangieri C, Pinkhasov A, Angulo M. Guanfacine Extended Release for the Reduction of Aggression, Attention-Deficit/Hyperactivity Disorder Symptoms, and Self-Injurious Behavior in Prader-Willi Syndrome-A Retrospective Cohort Study. *J Child Adolesc Psychopharmacol.* 2019;29:313-7.

<sup>31</sup> Soni S, Whittington J, Holland AJ, Webb T, Maina E, Boer H, et al. The course and outcome of psychiatric illness in people with Prader-Willi syndrome: Implications for management and treatment. *J Intellect Disabil Res.* 2007;51:32–42.

<sup>32</sup> Dalsgaard S, Ostergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. *Lancet.* 2015;385:2190-6.

<sup>33</sup> Mazaheri MM, Rae-Seebach RD, Preston HE, Schmidt M, Kountz-Edwards S, Field N et al. The impact of Prader-Willi syndrome on the family's quality of life and caregiving, and the unaffected siblings' psychosocial adjustment. *J Intellect Disabil Res.* 2013;57:861–73.

---

<sup>34</sup> Logan SL, Carpenter L, Leslie RS, Garrett-Mayer E, Hunt KJ, Charles J et al. Aberrant Behaviors and Co-occurring Conditions as Predictors of Psychotropic Polypharmacy among Children with Autism Spectrum Disorders. *J Child Adolesc Psychopharmacol*. 2015;25:323–36.

<sup>35</sup> Newcorn JH, Harpin V, Huss M, Lyne A, Sikirica V, Johnson M et al. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. *J Child Psychol Psychiatry*. 2016;57:717-28.

<sup>36</sup> Butterfield ME, Saal J, Young B, Young JL. Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study. *Psychiatry Res*. 2016;236:136-41.

<sup>37</sup> Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, et al. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry*. 2015;54:916-25.e2.

<sup>38</sup> Duis J, Pullen LC, Picone M, Friedman N, Hawkins S, Sannar E et al. Diagnosis and management of sleep disorders in Prader-Willi syndrome. *J Clin Sleep Med*. 2022;18:1687-96.

<sup>39</sup> Bakker NE, Lindberg A, Heissler J, Wollmann HA, Camacho-Hubner C, Hokken-Koelega AC. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of

---

Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database. *J Clin Endocrinol Metab.* 2017;102:1702–11.

<sup>40</sup> Sipila I, Sintonen H, Hietanen H, Apajasalo M, Alanne S, Viita A-M, et al. Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome. *Acta Paediatr.* 2010;99:1712–8.

<sup>41</sup> Singh D, Miller JL, Wassman ER, Butler MG, Foley Shenk A, Converse M et al. The Arduous Path to Drug Approval for the Management of Prader-Willi Syndrome: A Historical Perspective and Call to Action. *Int J Mol Sci.* 2023;24:11574.

<sup>42</sup> Balldin J, Berggren U, Eriksson E, Lindstedt G, Sundkler A. Guanfacine as an alpha-2-agonist inducer of growth hormone secretion--a comparison with clonidine. *Psychoneuroendocrinology.* 1993;18:45–55.

Figure 1. CONSORT Flow Diagram




Figure 1

**Figure 2. Forest Plot based on GEE Models**




Figure 2